Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration

Stefano Lazzeri, Michele Figus, Maria Sole Sartini, Fabio Scarinci, Giamberto Casini, Gianluca Guidi, Gaetano Cupo, Andrea Cacciamani, Vincenzo Fasanella, Luca Agnifili, Paolo Piaggi, Monica Varano, Guido Ripandelli, Marco Nardi, Mariacristina Parravano

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the effects of intravitreal ranibizumab monotherapy on predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Materials and Methods: Twenty-two consecutive eyes with hemorrhagic neovascularization were treated with 3 monthly intravitreal ranibizumab injections. Additional injections were administered according to retreatment criteria during 12 months of follow-up. Results: A mean of 6.64 ± 1.36 injections was administered. Overall, the mean visual acuity increased from 10.90 ± 6.02 to 12.81 ± 8.34 ETDRS letters (p > 0.05) at 12 months. The 'early treatment group' gained a mean of 2.83 ± 2.24 ETDRS letters (p <0.05), while the 'late treatment group' gained a mean of 0.30 ± 1.25 ETDRS letters (p > 0.05) with significant differences between the groups (p <0.05). A progressive resolution of macular bleeding was registered in 20 patients (mean time: 5.3 ± 1.6 months). Conclusions: Ranibizumab injections can be considered a beneficial approach for the management of predominantly hemorrhagic choroidal neovascularization with foveal involvement associated with age-related macular degeneration. Furthermore, the time interval between hemorrhage and the first injection seems to be an important predicting factor of final visual acuity.

Original languageEnglish
Pages (from-to)74-81
Number of pages8
JournalOphthalmologica
Volume233
Issue number2
DOIs
Publication statusPublished - Mar 6 2015

Keywords

  • Age-related macular degeneration
  • Fundus-related microperimetry
  • Intravitreal injections
  • Intravitreal ranibizumab
  • Predominantly hemorrhagic choroidal neovascularization

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Medicine(all)

Fingerprint Dive into the research topics of 'Intravitreal ranibizumab for predominantly hemorrhagic choroidal neovascularization in age-related macular degeneration'. Together they form a unique fingerprint.

  • Cite this